Literature DB >> 15565351

Barriers to effective management of osteoporosis in moderate and minimal trauma fractures: a prospective study.

Dana Bliuc1, Cynthia R Ong, John A Eisman, Jacqueline R Center.   

Abstract

Osteoporosis management is suboptimal even for high-risk people with a history of prior fracture. There is also evidence that individuals with moderate trauma fracture have a lower bone density and are at higher risk of subsequent fracture. This study aimed to define factors influencing the management of individuals at risk for osteoporosis and to examine the risk profiles of individuals with minimal and moderate trauma fractures. Consecutive fracture patients (n =218) treated in the outpatient fracture clinic in St Vincent's Hospital, Sydney, over a 15-month period (February 2002-July 2003) were interviewed. Fracture risk factors, prior investigation and treatment for osteoporosis were collected and participants were contacted after 3 months to ascertain follow-up. Risk factors for osteoporosis including family history, low dietary calcium and conditions associated with bone loss were similar between low- and moderate-trauma groups and between sexes. Even though half of participants had had a prior fracture, only 34% had a bone density scan and 16% were on anti-resorptive treatment. There was a minimal (6%) increase in the rates of investigation and treatment at the 3-month follow-up, and less in the moderate trauma group and males. Independent predictors for being investigated for osteoporosis were: age over 50, prior fracture and female gender, while predictors for treatment were: age over 50 and having been investigated. This study has confirmed low rates of investigation and treatment even in individuals who have already suffered a prior fracture, and especially in those <50 and in males. People with moderate and minimal trauma fractures had similar risk factors for osteoporosis, including a similarly high proportion of prior fractures. These findings support the concept that people with moderate trauma fractures are at higher subsequent fracture risk, yet are neither investigated nor treated. This study highlights the need for further exploration of barriers to osteoporosis management.

Entities:  

Mesh:

Year:  2004        PMID: 15565351     DOI: 10.1007/s00198-004-1788-x

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  28 in total

Review 1.  Guidelines for treatment of osteoporosis in men.

Authors:  T Diamond; P Sambrook; M Williamson; L Flicker; C Nowson; M Fiatarone-Singh; S Lord; L Ferris; S O'Neil; A MacLennan
Journal:  Aust Fam Physician       Date:  2001-08

2.  Direct clinical and welfare costs of osteoporotic fractures in elderly men and women.

Authors:  A Randell; P N Sambrook; T V Nguyen; H Lapsley; G Jones; P J Kelly; J A Eisman
Journal:  Osteoporos Int       Date:  1995       Impact factor: 4.507

3.  How well are community-living women treated for osteoporosis after hip fracture?

Authors:  S Bellantonio; R Fortinsky; K Prestwood
Journal:  J Am Geriatr Soc       Date:  2001-09       Impact factor: 5.562

4.  Awareness of osteoporosis and compliance with management guidelines in patients with newly diagnosed low-impact fractures.

Authors:  H Castel; D Y Bonneh; M Sherf; Y Liel
Journal:  Osteoporos Int       Date:  2001       Impact factor: 4.507

5.  Age- and gender-specific rate of fractures in Australia: a population-based study.

Authors:  K M Sanders; E Seeman; A M Ugoni; J A Pasco; T J Martin; B Skoric; G C Nicholson; M A Kotowicz
Journal:  Osteoporos Int       Date:  1999       Impact factor: 4.507

6.  The exclusion of high trauma fractures may underestimate the prevalence of bone fragility fractures in the community: the Geelong Osteoporosis Study.

Authors:  K M Sanders; J A Pasco; A M Ugoni; G C Nicholson; E Seeman; T J Martin; B Skoric; S Panahi; M A Kotowicz
Journal:  J Bone Miner Res       Date:  1998-08       Impact factor: 6.741

7.  Refractures in patients at least forty-five years old. a prospective analysis of twenty-two thousand and sixty patients.

Authors:  C M Robinson; M Royds; A Abraham; M M McQueen; C M Court-Brown; J Christie
Journal:  J Bone Joint Surg Am       Date:  2002-09       Impact factor: 5.284

8.  Management of osteoporosis in women with peripheral osteoporotic fractures after 50 years of age: a study of practices.

Authors:  Daniel Briançon; Jean-Baptiste de Gaudemar; Romain Forestier
Journal:  Joint Bone Spine       Date:  2004-03       Impact factor: 4.929

9.  The decision to accept treatment for osteoporosis following hip fracture: exploring the woman's perspective using a stage-of-change model.

Authors:  K F Mauck; M T Cuddihy; R T Trousdale; G R Pond; V S Pankratz; L J Melton
Journal:  Osteoporos Int       Date:  2002-07       Impact factor: 4.507

10.  Osteoporotic fracture: missed opportunity for intervention.

Authors:  Leah Port; Jacqueline Center; N Kathy Briffa; Tuan Nguyen; Robert Cumming; John Eisman
Journal:  Osteoporos Int       Date:  2003-08-07       Impact factor: 4.507

View more
  15 in total

1.  Cost-effectiveness of the Concord Minimal Trauma Fracture Liaison service, a prospective, controlled fracture prevention study.

Authors:  M S Cooper; A J Palmer; M J Seibel
Journal:  Osteoporos Int       Date:  2011-09-28       Impact factor: 4.507

2.  Hip fracture and other predictors of anti-osteoporosis drug use in Norway.

Authors:  H M Devold; A J Søgaard; A Tverdal; J A Falch; K Furu; H E Meyer
Journal:  Osteoporos Int       Date:  2012-07-10       Impact factor: 4.507

Review 3.  The definition and clinical significance of nonvertebral fractures.

Authors:  Jacqueline R Center
Journal:  Curr Osteoporos Rep       Date:  2010-12       Impact factor: 5.096

4.  Targeted intervention reduces refracture rates in patients with incident non-vertebral osteoporotic fractures: a 4-year prospective controlled study.

Authors:  A Lih; H Nandapalan; M Kim; C Yap; P Lee; K Ganda; M J Seibel
Journal:  Osteoporos Int       Date:  2010-11-24       Impact factor: 4.507

5.  Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2006-11-01

6.  Community pharmacist-initiated screening program for osteoporosis: randomized controlled trial.

Authors:  N Yuksel; S R Majumdar; C Biggs; R T Tsuyuki
Journal:  Osteoporos Int       Date:  2009-06-05       Impact factor: 4.507

7.  A multifaceted intervention to improve treatment of osteoporosis in postmenopausal women with wrist fractures: a cluster randomized trial.

Authors:  A Cranney; M Lam; L Ruhland; R Brison; M Godwin; M M Harrison; M B Harrison; T Anastassiades; J M Grimshaw; I D Graham
Journal:  Osteoporos Int       Date:  2008-07-16       Impact factor: 4.507

Review 8.  Drug Insight: choosing a drug treatment strategy for women with osteoporosis-an evidence--based clinical perspective.

Authors:  Piet P Geusens; Christian H Roux; David M Reid; Willem F Lems; Silvano Adami; Jonathan D Adachi; Philip N Sambrook; Kenneth G Saag; Nancy E Lane; Marc C Hochberg
Journal:  Nat Clin Pract Rheumatol       Date:  2008-04-08

9.  Characteristics of patients with fragility hip fractures in the northern Kyushu district in Japan: a multicenter prospective registry based on an electronic data capture system.

Authors:  Akiko Oyamada; Yoshihiro Matsumoto; Yoshifumi Wakata; Atsushi Kimura; Ko Ikuta; Kuniyoshi Tsuchiya; Naohisa Tayama; Shinji Tomari; Hisaaki Miyahara; Takao Mae; Hirokazu Shiraishi; Taichi Saito; Takeshi Arizono; Kozo Kaji; Taro Mawatari; Masami Fujiwara; Riku Sakimura; Kunichika Shin; Kenichi Ninomiya; Kazutoshi Nakaie; Yasuaki Antoku; Shoji Tokunaga; Naoki Nakashima; Yukihide Iwamoto; Yasuharu Nakashima
Journal:  J Bone Miner Metab       Date:  2017-10-12       Impact factor: 2.626

10.  Impact of osteoporotic fracture type and subsequent fracture on mortality: the Tromsø Study.

Authors:  D Alarkawi; D Bliuc; T Tran; L A Ahmed; N Emaus; A Bjørnerem; L Jørgensen; T Christoffersen; J A Eisman; J R Center
Journal:  Osteoporos Int       Date:  2019-10-26       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.